BOXED WARNING QT prolongation/torsade de pointes reported at or below recommended doses, some fatal; reserve for patients failing other treatments; 12-lead ECG before use.
FDA dosing
Population
Start
Target
Max
Perioperative nausea/vomiting (refractory)
Adults
2.5 mg IM or slow IV
—
Additional 1.25 mg PRN
Perioperative nausea/vomiting (refractory)
Children 2-12 yr
0.1 mg/kg IM or IV (max initial)
—
0.1 mg/kg initial
Renal Undefined
Hepatic Undefined
Instructions
Give IM or slow IV
Perform 12-lead ECG before dosing and monitor 2-3 hours after treatment
Initiate at a low dose and titrate upward with caution
Contraindications
Known or suspected QT prolongation, including congenital long QT syndrome